H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report)’s share price was down 49.5% during trading on Thursday . The stock traded as low as $2.02 and last traded at $2.02. Approximately 400 shares traded hands during mid-day trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Down 49.5 %
The firm’s 50-day moving average is $2.02 and its 200 day moving average is $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
See Also
- Five stocks we like better than H-CYTE
- What is a buyback in stocks? A comprehensive guide for investors
- 5 Best Gold ETFs for March to Curb Recession Fears
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
- Short Selling: How to Short a Stock
- Why Smart Investors Are Watching These 3 Undervalued Stocks
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
